AbbVie Inc., through its subsidiary Allergan Aesthetics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval application for SKINVIVE by JUVÉDERM®. This application seeks to expand the indication of SKINVIVE to include the reduction of neck lines, aiming to improve neck appearance. Already approved in the U.S. for enhancing cheek skin smoothness in adults over 21, SKINVIVE by JUVÉDERM® could become the first hyaluronic acid injectable treatment option targeting neck lines if approved. The application is supported by a clinical study that met all primary and secondary endpoints.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。